Litcius/Paper detail

Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients

Monica Calderón-Goercke, Santos Castañeda, Vicente Aldasoro, Ignacio Villa, C. Moriano, Susana Romero-Yuste, Javier Narváez, Catalina Gómez‐Arango, Eva Pérez‐Pampín, R. Melero, E. Becerra, Marcelino Revenga, Noelia Álvarez-Rivas, Carles Galisteo, Francisca Sivera, Eugenio de Miguel, D. Prieto-Peña, Miguel Á. González‐Gay, José L. Hernández, Ricardo Blanco

2021Seminars in Arthritis and Rheumatism28 citationsDOI

Topics & Concepts

MedicineTocilizumabGiant cell arteritisRefractory (planetary science)Observational studyInternal medicineMulticenter studyDermatologyVasculitisRheumatoid arthritisRandomized controlled trialPhysicsAstrobiologyDiseaseVasculitis and related conditionsOtitis Media and Relapsing PolychondritisCoagulation, Bradykinin, Polyphosphates, and Angioedema
Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients | Litcius